Specificity of effector T lymphocytes in autologous graft-versus-host disease: Role of the major histocompatibility complex class II invariant chain peptide

被引:61
作者
Hess, AD
Bright, EC
Thoburn, C
Vogelsang, GB
Jones, RJ
Kennedy, MJ
机构
关键词
D O I
10.1182/blood.V89.6.2203
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Administration of the immunosuppressive drug cyclosporine after autologous bone marrow transplantation induces a systemic autoimmune syndrome resembling graft-versus-host disease (GVHD). This syndrome termed autologous GVHD has significant antitumor activity. Associated with autologous GVHD is the development of T lymphocytes that recognize major histocompatibility complex (MHC) class II determinants, including self. The present studies attempted to characterize and define the molecular specificity of the effector T lymphocytes in autologous GVHD induced in patients with metastatic breast cancer. The results suggest that the effector cells associated with human autologous GVHD are CD8(+) T lymphocytes expressing the alpha/beta T-cell receptor, Additional studies show that the effector T cells recognize MHC class II antigens in association with a peptide from the invariant chain (CLIP). Pretreatment of autologous lymphoblast target cells with anti-CLIP antibody completely blocked lysis mediated by autologous GVHD effector T cells, On the other hand, force loading this peptide markedly enhanced the susceptibility of the target cells to recognition by the autoreactive T cells. The recognition of the MHC class II CLIP complex may account for the novel specificity of the effector T cells associated with human autologous GVHD, Moreover, identification of the target peptide may allow for the development of novel immunotherapeutic strategies to enhance the antitumor efficacy of autologous GVHD. (C) 1997 by The American Society of Hematology.
引用
收藏
页码:2203 / 2209
页数:7
相关论文
共 33 条
  • [21] PHASE-I TRIAL OF INTRAVENOUS CYCLOSPORINE TO INDUCE GRAFT-VERSUS-HOST DISEASE IN WOMEN UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR BREAST-CANCER
    KENNEDY, MJ
    VOGELSANG, GB
    BEVERIDGE, RA
    FARMER, ER
    ALTOMONTE, V
    HUELSKAMP, AM
    DAVIDSON, NE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) : 478 - 484
  • [22] PHASE-I TRIAL OF INTERFERON-GAMMA TO POTENTIATE CYCLOSPORINE-INDUCED GRAFT-VERSUS-HOST DISEASE IN WOMEN UNDERGOING AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR BREAST-CANCER
    KENNEDY, MJ
    VOGELSANG, GB
    JONES, RJ
    FARMER, ER
    HESS, AD
    ALTOMONTE, V
    HUELSKAMP, AM
    DAVIDSON, NE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (02) : 249 - 257
  • [23] HIGH-DOSE CHEMOTHERAPY WITH REINFUSION OF PURGED AUTOLOGOUS BONE-MARROW FOLLOWING DOSE-INTENSE INDUCTION AS INITIAL THERAPY FOR METASTATIC BREAST-CANCER
    KENNEDY, MJ
    BEVERIDGE, RA
    ROWLEY, SD
    GORDON, GB
    ABELOFF, MD
    DAVIDSON, NE
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (13) : 920 - 926
  • [24] INTERACTIONS BETWEEN STAPHYLOCOCCAL SUPERANTIGENS AND HUMAN T-CELL CLONES ARE PREDOMINANTLY BUT NOT EXCLUSIVELY GOVERNED BY THEIR T-CELL RECEPTOR V-BETA USAGE
    LUNDIN, KEA
    BRINCHMANN, JE
    HANSEN, T
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1994, 39 (04) : 387 - 394
  • [25] SUPERMOTIFS ENABLE NATURAL INVARIANT CHAIN-DERIVED PEPTIDES TO INTERACT WITH MANY MAJOR HISTOCOMPATIBILITY COMPLEX-CLASS-II MOLECULES
    MALCHEREK, G
    GNAU, V
    JUNG, G
    RAMMENSEE, HG
    MELMS, A
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (02) : 527 - 536
  • [26] NATALI PG, 1983, CANCER RES, V43, P660
  • [27] Noga S J, 1992, J Hematother, V1, P75, DOI 10.1089/scd.1.1992.1.75
  • [28] PARHAM P, 1983, J IMMUNOL, V131, P2895
  • [29] HLA-DR MOLECULES FROM AN ANTIGEN-PROCESSING MUTANT-CELL LINE ARE ASSOCIATED WITH INVARIANT CHAIN PEPTIDES
    RIBERDY, JM
    NEWCOMB, JR
    SURMAN, MJ
    BARBOSA, JA
    CRESSWELL, P
    [J]. NATURE, 1992, 360 (6403) : 474 - 477
  • [30] RUVOLO P, 1995, TRANSPLANT P, V27, P1363